PROTEOMA is created with the objective to substantially enhance biotechnological tools, Molecular Biology, Cellular Biology and pharmacology in Biomedicine, to give vital information in a clinical case regarding the diagnoses and treatment on a wide spectrum of neurodegenerative, inflammatory, immune and autoimmune, neoplastic, aging diseases, etc., influencing in the molecular diagnosis and advance therapies (nanobiological) for a personalized medicine. It’s a multidisciplinary team composed by doctors, chemical engineers, biochemists, and pharmacological biologists. Our team has the proved experience in both basic and translational experience, as well as the industry, and has developed an array proteomic test based on biotechnology, allowing a registration of implicated markers in the aforementioned diseases, and provides the physicians a deep knowledge of the pathological condition in the patient on a molecular level, and based on it, the proposal of new nanobiological therapies, just as new therapies for control, improvement and resolution of different pathologies.
Dr. Ernesto Romero Lopez, with over 20 years of experience, is a leading pioneer in stem cell and immunotherapy technology. He holds a Bachelor of Science in General Medicine from Universidad Autónoma de Nayarit, Mexico, and a Master of Science in Regenerative Medicine from Universidad Catolica de Murcia, Madrid, Spain. After his training at the esteemed Nordic University, Dr. Lopez now serves as a stem cell specialist at Immunotherapy Regenerative Medicine in Puerto Vallarta, Mexico.
He has devoted two decades to successfully treating patients with stem cell treatments in South America and Europe. As a passionate advocate of biotechnological research, he founded the Bioplenum S.A de C.V institute. His research focuses on the application of mesenchymal stem cells for treating various autoimmune and chronic degenerative diseases.
RAÚL ROSALES IBÁÑEZ
Doctor of Science in Tissue Engineering in Medicine and Dentistry
Dental Surgeon with a PhD in Tissue Engineering in Medicine and Dentistry, specialized in biocompatibility assessments. Integral part of the Tissue Engineering Laboratory, contributing significant advancements in the field of oral health.
Brief CV Dr. Sinforiano J. Posadas: Bachelor of Chemistry and PhD in Biochemistry and Molecular Pathology (Summa Cum Laude by Unanimity). Extensive record of publications in high impact journals in the field of immunology / allergology, aging, hormones, cancer, vaccines, neurodegeneration, microbiology, some of them the best worldwide in their area and also Editor’s Choice, with an H index of 16 and more than 1000 citations to his works. More than 100 Communications, lectures, oral presentations to international and national congresses of different scientific / medical societies. Director and Principal Investigator and co-investigator in numerous projects at the national and international level, both in regional and national programs (Ministry of Science / Universities and FIS Health Research Fund / Carlos III Institute), Europeos Feder, Horizonte, Biomed. Researcher FullBright / MEC and Juan de La Cierva, with postdoctoral stays in Switzerland, Rome, London and UCLA. Director of R&D in the Biotech industry for more than 6 years. Member of various prestigious scientific and evaluation committees: FIS, ANEP, EQA, American Society of Physiology, American Academy of Asthma, Allergy and Immunology, European Allergy and Clinical Immnunology, etc … International award / gold medal in the International Invention Hall / patents in Geneva 2019. Currently developing new advanced therapies, consulting, personalized molecular diagnosis and prevention.
The tendency is towards a personalized medicine according to the Chemistry Nobel Prize.
Winner of the Nobel Price, Aaron Ciechanover: the revolution towards personalized medicine. Published: Tuesday, June 2nd, 2019 19:36
The type of medicine which uses information stored in genes, proteins and the environment of a person to prevent, diagnose and treat a disease.
The word «PROTEOME» comes from the expresion “proteins expressed from a genome”. It reffers to a complex composition of proteins expressed and modified by a specific cell, tissue or organ at a certain moment under determine conditions. The proteome constantly changes in response to a series of environmental, intracellular and extracellular signals, health or sickness, cellular developing phase and the effects of treatments.
We designed a new integral method for disease treating in personalized Biomolecular Medicine.
We obtain a large amount of data to design the therapeutic intervention, growth factors, adhesion molecules, homing cytokines and chemokines, immunological factors, TH1-TH2-TREG-TEH17, cytotoxicity and molecular stress, tumoral progression, metastasis and invasion markers, and anti-tumor factors.
A BIG PROGRESS IN PERSONALIZED MEDICINE
WHEN IS IT INDICATED?
IF THEY ARE NOT THE ONLY EXPLORABLE PROTEOMIC PARAMETERS
WHAT IS THE NOVELTY?
“Grouping/selection of exploratory parameters and the connection between them that allows the most efficient interpretation of the patient’s health status.
Initially, the only possible way of therapeutic intervention was MONOCLONAL ANTIBODIES, assuming all the innate side effects involved.
Due to the lack of noble medication, our project has gathered a team of experts from different European and American universities, with the goal to develop magistral nanotherapeutic formulas, able to modulate each of the targeted molecules through control of their metabolic pathways, Thus, PROTEOMA was born.
PERSONALIZED NANOBIOLOGICAL THERAPY
We base our nanobiological treatments on “pathways” implicated in the target molecules for new therapies.
CD155. WEAKLY EXPRESSED IN SEVERAL NORMAL HUMAN TISSUES, BUR FRECUENTLY OVERLY-EXPRESSED IN MALIGNANT HUMAN TUMORS.
THE OVER-EXPRESSION OF CD155 PROMOTES THE INVATION AND MIGRATION OF TUMORAL CELLS.
HELPS TUMORAL PROGRESSION AND BAD PROGNOSIS.
CD155 MAY BE CONSIDERED AS A MAIN OBJECTIVE FOR TUMORS OVER-EXPRESSIONG CD144.
IT HAS BEEN PROVED THAT LEVELS OF CD155 WERE SIGNIFICANTLY HIGHER IN SERUMS OF 262 PATIENTS WITH LUNG, GASTRIC, BREAST AND GYNECOLOGICAL CANCER THAN THE SERUM OF HEALTHY DONORS.
ARGINASE ENZYME HAS A SPECIAL RELEVANCE IN THE IMMUNE RESPONSE WHEN COMPETING FOR THE L-ARGNININE WITH ANOTHER ENZIME, THE INDUCING NITRIC-OXIGEN SYNTHETASE.
We obtain an individual proteomic molecular registration, which tells us about the molecular status of the sick or health individual, its functionality, its relation with the pathological state and also how to prevent diseases and other therapeutic interventions.
We base our nanobiological treatments in “pathways” involved in the target molecules for the new therapies
C/La Gitanilla n# 17, Promalaga I+D 29004 . Malaga. España